Pathways to drug development for autism spectrum disorders (Q37972081)

26 August 2017

Pathways to drug development for autism spectrum disorders (English)

1 reference

26 August 2017

autism spectrum disorder

0 references

autism

0 references

author name string

D R Hampson

series ordinal

1

1 reference

26 August 2017

S Gholizadeh

series ordinal

2

1 reference

26 August 2017

L K K Pacey

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

28 December 2011

1 reference

Clinical Pharmacology & Therapeutics

26 August 2017

1 reference

26 August 2017

91

1 reference

26 August 2017

2

1 reference

26 August 2017

189-200

1 reference

Management of symptoms in children with autism spectrum disorders: a comprehensive review of pharmacologic and complementary-alternative medicine treatments.

26 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Psychopharmacology of autistic spectrum disorders in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Bridging the gap between MRI and postmortem research in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Review of neuroimaging in autism spectrum disorders: what have we learned and where we go from here

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Evidence for a cerebellar role in reduced exploration and stereotyped behavior in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Brainstem, cerebellar and limbic neuroanatomical abnormalities in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Neuropathologic features in the hippocampus and cerebellum of three older men with fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Repetitive behavior and increased activity in mice with Purkinje cell loss: a model for understanding the role of cerebellar pathology in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Altered white matter fractional anisotropy and social impairment in children with autism spectrum disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Transcriptomic analysis of autistic brain reveals convergent molecular pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Dendritic spine pathology in neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Enhanced polyubiquitination of Shank3 and NMDA receptor in a mouse model of autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

The mGluR theory of fragile X mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Potential therapeutic interventions for fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Fragile X and autism: Intertwined at the molecular level leading to targeted treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

GABA(A) receptor downregulation in brains of subjects with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Decreased GAD65 mRNA levels in select subpopulations of neurons in the cerebellar dentate nuclei in autism: an in situ hybridization study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Non-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 tesla instrument.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Genetic deletion of regulator of G-protein signaling 4 (RGS4) rescues a subset of fragile X related phenotypes in the FMR1 knockout mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Association of family history of autoimmune diseases and autism spectrum disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Autism spectrum disorders and autistic traits: a decade of new twin studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Autism spectrum disorders--a genetics review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Functional impact of global rare copy number variation in autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Connecting genes to brain in the autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Rare De Novo and Transmitted Copy-Number Variation in Autistic Spectrum Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Immune transcriptome alterations in the temporal cortex of subjects with autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Signaling mechanisms regulating synapse formation and function in mental retardation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Dysregulation of mTOR signaling in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

FMRP mediates mGluR5-dependent translation of amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

hnRNP C promotes APP translation by competing with FMRP for APP mRNA recruitment to P bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Plasma cytokine profiles in Fragile X subjects: is there a role for cytokines in the pathogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Neuroglial activation and neuroinflammation in the brain of patients with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

The immune system's role in the biology of autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Mitochondrial dysfunction in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Maternal immune activation and autism spectrum disorder: interleukin-6 signaling as a key mechanistic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Antibodies against fetal brain in sera of mothers with autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Further characterization of autoantibodies to GABAergic neurons in the central nervous system produced by a subset of children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Maternal infection and immune involvement in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Innate and adaptive autoimmunity directed to the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Immune proteins in brain development and synaptic plasticity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Immune dysfunction in autism: a pathway to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Astrocytes prevent abnormal neuronal development in the fragile x mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Changing face of microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Immune function of astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Open-label add-on treatment trial of minocycline in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Mechanisms of GABA release from human astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Viral vector-mediated gene transfer for CNS disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Regulation of gene expression in adeno-associated virus vectors in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Reversal of neurological defects in a mouse model of Rett syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

Tuberous sclerosis: a primary pathology of astrocytes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.245

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2011.245

1 reference

26 August 2017

1 reference